Medicines Patent Pool Signs Agreement with Shilpa Medicare to Increase Generic Production

25 JUNE 2013: The Medicines Patent Pool, Shilpa Medicare, and Gilead Sciences have signed an agreement to increase access to treatments for HIV.

The agreement will allow Shilpa Medicare to produce five key HIV medicines for sale in 100 – 112 countries, depending on the medicine, and covering a majority of people living with HIV.

“We are delighted to be working with the Medicines Patent Pool and Gilead Sciences to speed the development of HIV treatments for people who need it and have struggled to access it,” said Mr. Vishnukant Bhutada, Managing Director of Shilpa Medicare. Reva Pharma, an associated company of Shilpa Medicare will assist in marketing Shilpa’s ARV products including coordinating with MPP and other stakeholders with regard to this therapy.

Shilpa is an active pharmaceutical ingredient (API) and dosage form manufacturing company based in India that has decided to enter the field of HIV medicines. Reva Pharma is a global pharmaceutical organisation that operates in regulated and emerging markets.

Shilpa Medicare joins five other generic manufacturers who are currently signed up to produce HIV medicines licensed to the MPP by Gilead Sciences in July 2011, including two API manufacturers. Adding Shilpa to this group will help ensure that the supply of key HIV medicines will grow to meet rising demands for HIV treatment.

The medicines covered in this agreement are: tenofovir, emtricitabine, cobicistat, elvitegravir and a combination of the four known as “the Quad.”

“We are excited to add Shilpa Medicare to our sub-­‐licensees, who are essential in working with us to achieve the aim of expanding access to quality, effective HIV treatment in developing countries,” said Greg Perry, Medicines Patent Pool Executive Director.

Under the agreement, Shilpa will also benefit from technology transfer to aid generic manufacture of these medicines. The four-­medicines-­in‐one Quad received approval from the US Food and Drug Administration on 27 August 2012. The Quad is important as it simplifies treatment delivery, which is particularly useful for people treating HIV in developing countries.

Comments are closed.